| Popis |
IntroductionPsoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data.MethodsThis was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment.ResultsFifty-four patients (70.4% male, mean age 46.9 +/- 13.4 years, weight 95.6 +/- 22.7 kg, disease duration 18.6 +/- 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naive. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) >= 20). Overall, the mean PASI decreased by 15.6 from 16.1 (+/- 5.0) at baseline to 0.5 (+/- 1.2) at the last visit. The primary endpoint of an absolute PASI <= 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician's Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes.ConclusionsLIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naive and biologic-experienced patients.
|